Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm Cmn (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,584,050
  • Shares Outstanding, K 21,000
  • Annual Sales, $ 108,970 K
  • Annual Income, $ -1,640 K
  • 36-Month Beta 0.97
  • Price/Sales 23.25
  • Price/Cash Flow 124.92
  • Price/Book 6.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.40 +6.63%
on 07/13/17
124.42 -1.10%
on 06/26/17
+2.85 (+2.37%)
since 06/21/17
3-Month
104.25 +18.03%
on 05/10/17
124.42 -1.10%
on 06/26/17
+18.66 (+17.88%)
since 04/21/17
52-Week
87.50 +40.63%
on 11/04/16
139.79 -11.98%
on 08/01/16
-8.91 (-6.75%)
since 07/21/16

Most Recent Stories

More News
Ligand Signs Agreement with Amgen, Grants Rights to Captisol

Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology...

LGND : 123.05 (+1.96%)
MRK : 62.63 (-0.49%)
NVS : 84.99 (-0.50%)
AMGN : 180.21 (+0.50%)
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand's Captisol...

LGND : 123.05 (+1.96%)
AMGN : 180.21 (+0.50%)
Ligand Pharm Set to Possibly Pullback After Yesterday's Rally of 2.38%

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $120.43 to a high of $123.79. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of...

LGND : 123.05 (+1.96%)
Ligand Gets Milestone Payment on Partner Drug FDA Approval

Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the...

LGND : 123.05 (+1.96%)
MRK : 62.63 (-0.49%)
NVS : 84.99 (-0.50%)
AMGN : 180.21 (+0.50%)
Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?

Ligand Pharmaceuticals (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND : 123.05 (+1.96%)
Key FDA Events to Watch Out for in Jun 2017

Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

LGND : 123.05 (+1.96%)
NVO : 42.95 (-1.38%)
SHPG : 164.03 (+2.38%)
RHHBY : 32.2700 (+0.22%)
PTLA : 66.04 (+1.15%)
ALKS : 57.73 (+0.35%)
NEOS : 6.60 (-2.22%)
Ligand (LGND) Signs Licensing Deal with xCella Biosciences

Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.

AGLE : 3.70 (+2.21%)
LGND : 123.05 (+1.96%)
VVUS : 1.24 (+1.64%)
MEIP : 3.02 (-1.63%)
Ligand Enters Into Worldwide OmniAb(R) Platform License Agreement With xCella Biosciences

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella Biosciences, Inc. Under the license,...

LGND : 123.05 (+1.96%)
Ligand Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.67%

Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $110.53 to a high of $113.21. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day...

LGND : 123.05 (+1.96%)
Ligand to Participate in Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:

LGND : 123.05 (+1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Support & Resistance

2nd Resistance Point 125.12
1st Resistance Point 124.08
Last Price 123.05
1st Support Level 121.06
2nd Support Level 119.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.